Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00079248
Recruitment Status : Unknown
Verified June 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : March 10, 2004
Last Update Posted : May 12, 2009
Information provided by:
National Cancer Institute (NCI)

March 8, 2004
March 10, 2004
May 12, 2009
March 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00079248 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer
UK Trial Of Hormone Replacement Therapy (HRT) In Women With A History Of Early Stage Breast Cancer

RATIONALE: Hormone replacement therapy may be effective in relieving symptoms of menopause, such as hot flashes, night sweats, and vaginal dryness, without causing a recurrence of breast cancer.

PURPOSE: This randomized clinical trial is studying hormone replacement therapy to see how well it works in relieving symptoms of menopause in postmenopausal women with previous stage I or stage II breast cancer.


  • Compare disease-free survival and overall survival of postmenopausal women with prior stage I or II breast cancer treated with hormone replacement therapy (HRT) vs nonhormonal alternatives to HRT.
  • Compare relief of menopausal symptoms and quality of life of patients treated with these regimens.
  • Compare cardiovascular and osteoporotic events in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, age (< 40 years vs ≥ 40 years), and years from diagnosis (≤ 2 vs > 2 to < 5 vs ≥ 5). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral or transdermal HRT comprising estrogen with or without progesterone for at least 2 years.
  • Arm II: Patients are offered advice on nonhormonal HRT alternatives. Menopausal symptoms are assessed at baseline, at 3, 6, and 12 months, every 6 months for 4 years, and then annually thereafter. Quality of life is assessed at baseline, at 3, 6, and 12 months, every 6 months for 1 year, and then annually thereafter.

Patients are followed every 6 months for 3 years and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 2,800-3,000 patients (1,400-1,500 per treatment arm) will be accrued for this study.

Not Applicable
Allocation: Randomized
Primary Purpose: Supportive Care
  • Breast Cancer
  • Hot Flashes
  • Menopausal Symptoms
  • Osteoporosis
  • Biological: therapeutic progesterone
  • Drug: conjugated estrogens
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided
Not Provided
Not Provided


  • Prior diagnosis of stage I or II breast cancer

    • No clinical evidence of recurrence
  • Meets criteria for 1 of the following:

    • Amenorrheic for at least the past 6 months

      • Radiotherapy- or chemically-induced ovarian suppression allowed
    • Prior surgical bilateral oophorectomy
  • Experiencing vasomotor symptoms (i.e., hot flashes or night sweats) with or without vaginal dryness
  • No undiagnosed postmenopausal bleeding
  • No ductal carcinoma in situ or lobular carcinoma in situ alone
  • Hormone receptor status:

    • Not specified



  • Postmenopausal


  • Female

Menopausal status

  • Postmenopausal

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • No severe, active liver disease with abnormal liver function tests
  • No acute, intermittent porphyria
  • Fibrinolysis and coagulation normal


  • Not specified


  • No prior deep vein thrombosis

    • Thrombophlebitis or superficial phlebitis alone allowed
  • No prior retinal vein thrombosis


  • No prior pulmonary embolism


  • Not pregnant
  • No prior alcohol, drug, or chemical abuse
  • No other prior or concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix


Biologic therapy

  • Not specified


  • No concurrent chemotherapy

Endocrine therapy

  • More than 3 months since prior oral or transdermal hormone replacement therapy (HRT)
  • More than 5 years since prior HRT implant
  • No other concurrent HRT
  • No concurrent gonadotropin-releasing hormone agonists (e.g., goserelin) if less than 2 years of planned treatment remains
  • No other concurrent low-dose progestins
  • No concurrent tibolone
  • No concurrent phytoestrogens (e.g., black cohosh, red clover, or soy)


  • See Disease Characteristics


  • See Disease Characteristics


  • No concurrent Hypericum perforatum (St. John's wort)
Sexes Eligible for Study: Female
Child, Adult, Older Adult
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
Not Provided
Not Provided
Institute of Cancer Research, United Kingdom
Not Provided
Investigator: Jenni Parmar, RN Institute of Cancer Research, United Kingdom
National Cancer Institute (NCI)
June 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP